Esra ÖZSOY ADIŞEN, Gonca SOYUDURU, A. Burhan AKSAKAL, İlkay KADIOĞLU ÖZER

The effect of isotretinoin on insulin resistance and adipocytokine levels in acne vulgaris patients

Background/aim: Recent data draw attention to the effect of body composition, insulin resistance, and adipocytokines to acne vulgaris(AV) development. The aim of this study was to assess the association of AV with insulin resistance and adipocytokine levels and toevaluate the effect of isotretinoin on insulin resistance and adipocytokine levels.Materials and methods: In 29 AV patients and 29 healthy volunteers, body mass index (BMI) and body fat mass (BFM), lipid,adiponectin, leptin, resistin, retinol binding protein-4 (RBP4), and insulin levels were measured and insulin resistance was assessed byHOMA-IR index in serum samples taken twice from patients before and after isotretinoin treatment.Results: In AV patients, pretreatment HOMA-IR and adipocytokine levels were not found to correlate with disease severity. With fivemonths of isotretinoin treatment, higher HOMA-IR values were found (P = 0.028). Isotretinoin therapy maintained lower mean resistinlevels (P = 0.016), higher mean RBP4 levels (P = 0.040), but not affected the mean adiponectin and leptin levels (P = 0.113, P = 0.125,respectively).Conclusions: All data suggests that five months of isotretinoin therapy in AV patients causes insulin resistance and the increase in insulin resistance is not dependent on age, BMI, BFM, and lipid levels of these patients.

PDF

___

1. Kraft J, Freiman A. Management of acne. CMAJ 2011; 183: E430-435.
2. Zaenglein AL, Thiboutot DM. Acne vulgaris. In: Bolognia JL, Jorizzo JL, Rapini RP, editors. Dermatology. 2nd ed. Spain: Mosby Elsevier; 2008. pp. 495-508.
3. Tom WL, Friedlander SF. Acne through the ages: case-based observations through childhood and adolescence. Clin Pediatr (Phila) 2008; 47: 639-651.
4. Williams HC, Dellavalle RP, Garner S. Acne vulgaris. Lancet 2012; 379: 361-372.
5. Cisneros FJ, Gough BJ, Patton RE, Ferguson SA. Serum levels of albumin, triglycerides, total protein and glucose in rats are altered after oral treatment with low doses of 13-cis-retinoic acid or all-trans-retinoic acid. J Appl Toxicol 2005; 25: 470-478.
6. Heliovaara MK, Remitz A, Reitamo S, Teppo AM, Karonen SL, Ebeling P. 13-cis-Retinoic acid therapy induces insulin resistance, regulates inflammatory parameters, and paradoxically increases serum adiponectin concentration. Metabolism 2007; 56: 786-791.
7. Koistinen HA, Remitz A, Koivisto VA, Ebeling P. Paradoxical rise in serum adiponectin concentration in the face of acidinduced insulin resistance 13-cis-retinoic. Diabetologia 2006; 49: 383-386.
8. Koistinen HA, Remitz A, Gylling H, Miettinen TA, Koivisto VA, Ebeling P. Dyslipidemia and a reversible decrease in insulin sensitivity induced by therapy with 13-cis-retinoic acid. Diabetes Metab Res Rev 2001; 17: 391-395.
9. Ertugrul DT, Karadag AS, Tutal E, Akin KO. Isotretinoin does not induce insulin resistance in patients with acne. Clin Exp Dermatol 2011; 36: 124-128.
10. Guzik TJ, Mangalat D, Korbut R. Adipocytokines - novel link between inflammation and vascular function. J Physiol Pharmacol 2006; 57: 505-28.
11. Kızılyel O, Metin MS, Elmas ÖF, Çayır Y, Aktaş A. Effects of oral isotretinoin on lipids and liver enzymes in acne patients. Cutis 2014; 94: 234-238.
12. Bener A, Lestringant GG, Ehlayel MS, Saarinen K, Takiddin AH. Treatment outcome of acne vulgaris with oral isotretinoin. J Coll Physicians Surg Pak 2009; 19: 49-51.
13. Zane LT, Leyden WA, Marqueling AL, Manos MM. A population-based analysis of laboratory abnormalities during isotretinoin therapy for acne vulgaris. Arch Dermatol 2006; 142: 1016-1022.
14. Stoll D, Binnert C, Mooser V, Tappy L. Short-term administration of isotretinoin elevates plasma triglyceride concentrations without affecting insulin sensitivity in healthy humans. Metabolism 2004; 53: 4-10.
15. Karadag AS, Ertugrul DT, Takci Z, Bilgili SG, Namuslu M, Ata N. The effect of isotretinoin on retinol-binding protein 4, leptin, adiponectin and insulin resistance in acne vulgaris patients. Dermatology 2015; 230: 70-74.
16. Timperley AC, Withnall RD, Rainford DJ. The development of insulin-dependent diabetes mellitus in renal transplant patient receiving oral isotretinoin. Nephrol Dial Transplant 1996; 11: 753.
17. Dicembrini I, Bardini G, Rotella CM. Association between oral isotretinoin therapy and unmasked latent immuno-mediated diabetes. Diabetes Care 2009; 32: e99.
18. Corbetta S, Angioni R, Cattaneo A, Beck-Peccoz P, Spada A. Effects of retinoid therapy on insulin sensitivity, lipid profile and circulating adipocytokines. Eur J Endocrinol 2006; 154: 83-86.
19. Mangelsdorf DJ, Ong ES, Dyck JA, Evans RM. Nuclear receptor that identifies a novel retinoic acid response pathway. Nature 1990; 345: 224-229.
20. Tilg H, Moschen AR. Role of adiponectin and PBEF/visfatin as regulators of inflammation involvement in obesity-associated diseases. Clin Sci (Lond) 2008; 114: 275-288.
21. Falcao-Pires I, Castro-Chaves P, Miranda-Silva D, Lourenco AP, Leite-Moreira AF. Physiological, pathological and potential therapeutic roles of adipokines. Drug Discov Today 2012; 17: 880-889.
22. Krskova-Tybitanclova K, Macejova D, Brtko J, Baculikova M, Krizanova O, Zorad S. Short term 13-cis-retinoic acid treatment at therapeutic doses elevates expression of leptin, GLUT4, PPARgamma and aP2 in rat adipose tissue. J Physiol Pharmacol 2008; 59: 731-743.
23. Iwaki M, Matsuda M, Maeda N, Funahashi T, Matsuzawa Y, Makishima M. Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes 2003; 52: 1655-1663.
24. Aydin K, Çetinözman F, Elcin G, Aksoy DY, Ucar F, Yildiz BO. Suppressed adiponectin levels and increased adiponectin response to oral glucose load in lean women with severe acne normalizes after isotretinoin treatment. Dermatology 2017; 233: 314-319.
25. Zhang Y, Matheny M, Zolotukhin S, Tumer N, Scarpace PJ. Regulation of adiponectin and leptin gene expression in white and brown adipose tissues: influence of beta3-adrenergic agonists, retinoic acid, leptin and fasting. Biochim Biophys Acta 2002; 1584: 115-122.
26. McIlroy GD, Delibegovic M, Owen C, Stoney PN, Shearer KD, McCaffery PJ. Fenretinide treatment prevents dietinduced obesity in association with major alterations in retinoid homeostatic gene expression in adipose, liver, and hypothalamus. Diabetes 2013; 62: 825-386.
27. Carbone F, La Rocca C, Matarese G. Immunological functions of leptin and adiponectin. Biochimie 2012; 94: 2082-2088.
28. Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol 2011; 11: 85-97.
29. Degawa-Yamauchi M, Bovenkerk JE, Juliar BE, Watson W, Kerr K, Jones R. Serum resistin (FIZZ3) protein is increased in obese humans. J Clin Endocrinol Metab 2003; 88: 5452-5455.
30. Nagaev I, Smith U. Insulin resistance and type 2 diabetes are not related to resistin expression in human fat cells or skeletal muscle. Biochem Biophys Res Commun 2001; 285: 561-564.
31. Janke J, Engeli S, Gorzelniak K, Luft FC, Sharma AM. Resistin gene expression in human adipocytes is not related to insulin resistance. Obes Res 2002; 10: 1-5.
32. Felipe F, Bonet ML, Ribot J, Palou A. Modulation of resistin expression by retinoic acid and vitamin A status. Diabetes 2004; 53: 882-889.
33. Kotnik P, Fischer-Posovszky P, Wabitsch M. RBP4: a controversial adipokine. Eur J Endocrinol 2011; 165: 703-711.
34. Graham TE, Yang Q, Bluher M, Hammarstedt A, Ciaraldi TP, Henry RR. Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med 2006; 354: 2552-2563.